Grace Halsey

The FDA Fast Track designation for NRX-100 (IV, preservative-free ketamine) expands by 10-fold the potential treatment population that seriously considers suicide.

Insulin delivered via nasal spray in this first-in-human PET imaging study was observed in 11 key brain areas relevant to cognitive decline, validating a new research avenue.

The oral peptide that selectively targets IL-23 offers a novel approach to quelling the inflammatory process that underlies plaque psoriasis.

The obesity and lifestyle medicine specialist says while research on the question continues, a focus on optimizing nutritional health during treatment is essential.

Health information permeates social media platforms exposing Americans to advice, even when they don't want it. The good news? Not many trust it!

The 2 new plasma assays to enhance Alzheimer’s disease research will support disease staging, predicting disease progression, and monitoring treatment outcome.

Jonathan Bonnet, MD, MPH, encourages primary care clinicians to embrace GLP-1 therapy where appropriate to stem multiple risk factors for downstream chronic diseases.

The investigational daily oral GLP-1 RA met the primary endpoint for body weight reduction at 72 weeks and also improved a range of cardiovascular risk factors.

Fremanezumab is now the only CGRP antagonist indicated for prevention of migraine in adults and preventive treatment of episodic migraine in pediatric patients.

Since his Senate approval as head of HHS in February, RFK Jr has enacted and/or proposed seismic changes to US vaccine policy that will impact your daily care of patients.

An NHANES-based cross sectional study found that 1 in 5 of the treatment-eligible youth lacked adequate insurance and one-third had no routine place for health care.

If primary care clinicians are to meet the cognitive screening demands that are growing with an aging population, they need the sharpest tools in the box, this expert says.

A cognitive health assessment will soon be as routine as taking blood pressure or pulse oximetry, says neurocognitive researcher David J. Libon, PhD. He talks more about that future.

The NaV1.8 ion channel inhibitor was planned as a follow-up to the company's first nonopioid for acute pain, suzetrigine, approved by the FDA in January 2025.

For initiating colorectal cancer screening in average-risk young adults, a default mailed outreach strategy outperformed 3 active choice options in a randomized study.

Acoustic variables, like shimmer and jitter, that are typically undetectable in human speech can be detected with tablet technology and serve as biomarkers for mental acuity.

Adequate sleep tops the 4 elements most important to CV health after menopause, with blood pressure, glucose levels, and smoking status close behind.

The ability to observe an early marker of Alzheimer disease progression noninvasively marks a new phase of research with potential for improved disease management.

The FDA requires all manufacturers of opioid pain medications to revise labeling to emphasize and explain risks with long-term use.

Bonnet says a clear understanding of a patient's weight and emotional history are critical to ensure optimal use of GLP-1 therapy in a successful weight management program.

Only 92.5% of kindergartners received the recommended 2-shot MMR series in 2024-25 and rates were similarly low for DTaP and polio, according to the CDC.

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

In the SURPASS-CVOT trial, tirzepatide reduced MACE-3 by 8% and all-cause mortality by 16% compared with dulaglutide, while also reducing HbA1c and weight.

The guideline is the first in a series that will focus on diagnosis, treatment, and care of Alzheimer disease and all other dementias, according to the association.

Coauthor of a recent joint advisory, Jonathan Bonnet, MD, MPH, explains how it emerged in response to the growing use of GLP-1 medications for obesity treatment.

In this short conversation, Libon underscores how time-based measures during assessment can reflect subtle neurocognitive changes, augmenting traditional screening.

Clinical skepticism about the parity in effectiveness of epinephrine delivered via nasal spray vs autoinjector is rooted in fixed assumptions that bear examination, authors say.

The European Commission is expected to make a final regulatory decision on the anti-amyloid therapy in the coming months, Lilly said.

The brain changes that lead to cognitive and behavioral changes referred to as dementia have multiple potential etiologies; not all dementia is Alzheimer disease.